SCHEMBL3016855

SCHEMBL3016855

O=S(=O)(c1cc(Cl)ccc1Cl)N1CCN(c2nc(-c3ccc(Cl)c(Cl)c3)cs2)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 2/20 0.60
SMN1; SMN2 Q16637 6/20 0.54
ALDH1A1 P00352 3/20 0.54
L3MBTL1 Q9Y468 2/20 0.54
MAPT P10636 7/20 0.52
LMNA P02545 4/20 0.52
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
MAPK1 P28482 4/20 0.49
RAB9A P51151 2/20 0.48
NPC1 O15118 1/20 0.48
TSHR P16473 2/20 0.48
ALOX15 P16050 1/20 0.48
USP2 O75604 2/20 0.46
RECQL P46063 1/20 0.46
HSD17B10 Q99714 1/20 0.46
NPSR1 Q6W5P4 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3003605 0.93 SMN1; SMN2 (0.58) ARSMN1; SMN2ALDH1A1L3MBTL1MAPT
SCHEMBL3012781 0.93 SMN1; SMN2 (0.56) ARSMN1; SMN2ALDH1A1L3MBTL1MAPT
SCHEMBL3003663 0.93 AR (0.58) ARSMN1; SMN2ALDH1A1L3MBTL1MAPT
SCHEMBL3009026 0.91 SMN1; SMN2 (0.56) ARSMN1; SMN2ALDH1A1L3MBTL1MAPT
SCHEMBL3012826 0.91 SMN1; SMN2 (0.56) ARSMN1; SMN2ALDH1A1L3MBTL1MAPT
SCHEMBL3002107 0.90 SMN1; SMN2 (0.52) ARSMN1; SMN2ALDH1A1L3MBTL1MAPT
SCHEMBL3011536 0.90 SMN1; SMN2 (0.50) ARSMN1; SMN2ALDH1A1L3MBTL1MAPT
SCHEMBL3019901 0.89 SMN1; SMN2 (0.54) ARSMN1; SMN2ALDH1A1L3MBTL1MAPT
SCHEMBL3015400 0.89 AR (0.60) ARSMN1; SMN2ALDH1A1L3MBTL1MAPT
SCHEMBL3015861 0.89 MAPK1 (0.63) ARSMN1; SMN2ALDH1A1L3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885SMN1; SMN2 1/4885ALDH1A1 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.